News | February 06, 2026
Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
This approval authorizes the company to export Ibuprofen to the Chinese markets
The consignment of USFDA qualified Metformin (1000mg) was received by the province of Mendoza for distribution in the public health system
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Subscribe To Our Newsletter & Stay Updated
